http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 13 Oct 2026 10:51:31 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+BMBL+FUN+MUB+AVTR+CCC+ITUB+SPAX+INSM+AMRZ/27179567.html <p>Increasing unusual option volume: BMBL FUN MUB AVTR CCC ITUB SPAX INSM AMRZ</p> http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+BMBL+FUN+MUB+AVTR+CCC+ITUB+SPAX+INSM+AMRZ/27179567.html Tue, 13 Oct 2026 10:51:31 -0400 AVTR http://www.streetinsider.com/Option+EPS+Action/Increasing+unusual+option+volume%3A+BMBL+FUN+MUB+AVTR+CCC+ITUB+SPAX+INSM+AMRZ/27179567.html <p>Increasing unusual option volume: BMBL FUN MUB AVTR CCC ITUB SPAX INSM AMRZ</p> http://www.streetinsider.com/Option+EPS+Action/Increasing+unusual+option+volume%3A+BMBL+FUN+MUB+AVTR+CCC+ITUB+SPAX+INSM+AMRZ/27179567.html Tue, 13 Oct 2026 10:51:31 -0400 AVTR http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2417+at+TD+Cowen/27178855.html TD Cowen analyst Dan Brennan raised the price target on Avantor Inc. (NYSE: AVTR) to $17.00 (from $15.00) while maintaining a rating. http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2417+at+TD+Cowen/27178855.html Tue, 13 Oct 2026 09:30:36 -0400 AVTR http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2415+at+Morgan+Stanley/27177718.html Morgan Stanley analyst Tejas Savant raised the price target on Avantor Inc. (NYSE: AVTR) to $15.00 (from $14.00) while maintaining a Equalweight rating. http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2415+at+Morgan+Stanley/27177718.html Tue, 13 Oct 2026 08:23:14 -0400 AVTR http://www.streetinsider.com/Options/Avantor+%28AVTR%29+4K+contracts+of+January+16+calls+trade/27168419.html <p>Avantor (NYSE: AVTR) 30-day option implied volatility is at 24; compared to its 52-week range of 32 to 88 with a focus on 4K contracts of January 16 calls. </p> http://www.streetinsider.com/Options/Avantor+%28AVTR%29+4K+contracts+of+January+16+calls+trade/27168419.html Fri, 09 Oct 2026 05:05:43 -0400 AVTR http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2417+at+Baird/27163576.html Baird analyst Catherine Schulte raised the price target on Avantor Inc. (NYSE: AVTR) to $17.00 (from $16.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2417+at+Baird/27163576.html Thu, 08 Oct 2026 07:22:54 -0400 AVTR http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2415+at+Barclays/27156931.html Barclays analyst Luke Sergott raised the price target on Avantor Inc. (NYSE: AVTR) to $15.00 (from $13.00) while maintaining a Underweight rating. http://www.streetinsider.com/Analyst+PT+Change/Avantor+Inc.+%28AVTR%29+PT+Raised+to+%2415+at+Barclays/27156931.html Wed, 07 Oct 2026 03:48:40 -0400 AVTR http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html <p>KeyBanc analyst Paul Knight previews the Life Sciences Tools & Services earnings.</p><p>The analyst commented: "Earnings begin with TMO and DHR on 10/21 and data suggests accelerating growth in Life Science markets. Our revenue growth rate table (Fig. 1), ranked by easiest 3Q to 2Q comparisons, shows the biggest potential beats at WST (6.9% 3QE vs 12.7% 2Q), DHR (2.3% vs 3.0%), RGEN (11.2% vs 13.0%), STVN (7.7% vs 8.2%), WAT (9.0% vs 9.0%), and TMO (4.7% vs 4.7%). Signs of faster than expected Tools market growth are FDA approvals on pace for a record year with 51 through Oct 1 http://www.streetinsider.com/Analyst+Comments/KeyBanc%27s+Preview+of+%27Biggest+Potential+Beats+in+Life+Science%27/27146293.html Mon, 05 Oct 2026 08:40:35 -0400 AVTR CYRX DHR MLAB RGEN RVTY SATG STVN TMO WAT WSI http://www.streetinsider.com/Press+Releases/Avantor%C2%AE+to+Report+Third+Quarter+2026+Earnings+on+Wednesday%2C+October+28%2C+2026/27130857.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.radnor" idsrc="xmltag.org" >RADNOR, Pa.</location></span>, <span class="legendSpanClass"><chron>Oct. 1, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:AVTR" idsrc="xmltag.org" >Avantor, Inc.</span> (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2026 financial results before the market opens on Wednesday, October 28, and will hold a related conference call on the same day at 8:00 a.m. Eastern Time.</p> http://www.streetinsider.com/Press+Releases/Avantor%C2%AE+to+Report+Third+Quarter+2026+Earnings+on+Wednesday%2C+October+28%2C+2026/27130857.html Thu, 01 Oct 2026 06:05:00 -0400 AVTR http://www.streetinsider.com/PRNewswire/Avantor%C2%AE+to+Report+Third+Quarter+2026+Earnings+on+Wednesday%2C+October+28%2C+2026/27130857.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.pa.radnor" idsrc="xmltag.org" >RADNOR, Pa.</location></span>, <span class="legendSpanClass"><chron>Oct. 1, 2026</chron></span> /PRNewswire/ -- <span value="NYSE:AVTR" idsrc="xmltag.org" >Avantor, Inc.</span> (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, will release its third quarter 2026 financial results before the market opens on Wednesday, October 28, and will hold a related conference call on the same day at 8:00 a.m. Eastern Time.</p> http://www.streetinsider.com/PRNewswire/Avantor%C2%AE+to+Report+Third+Quarter+2026+Earnings+on+Wednesday%2C+October+28%2C+2026/27130857.html Thu, 01 Oct 2026 06:05:00 -0400 AVTR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+21++Filed+by%3A+Garner+Todd+W/27097063.html si-local-file:///var/storage/secattach/20260923/27097063.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+21++Filed+by%3A+Garner+Todd+W/27097063.html Wed, 23 Sep 2026 16:30:00 -0400 AVTR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+21++Filed+by%3A+Garner+Todd+W/27097016.html si-local-file:///var/storage/secattach/20260923/27097016.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+21++Filed+by%3A+Garner+Todd+W/27097016.html Wed, 23 Sep 2026 16:28:00 -0400 AVTR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+17/27082924.html si-local-file:///var/storage/secattach/20260921/27082924.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+17/27082924.html Mon, 21 Sep 2026 07:14:00 -0400 AVTR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+17/27082895.html si-local-file:///var/storage/secattach/20260921/27082895.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Avantor%2C+Inc.+++++++++++++For%3A+Sep+17/27082895.html Mon, 21 Sep 2026 07:09:00 -0400 AVTR http://www.streetinsider.com/Management+Changes/Avantor+names+Todd+Garner+as+CFO+effective+Sept.+21/27082503.html <p>Avantor, Inc. (NYSE: AVTR) has appointed Todd Garner as Executive Vice President and Chief Financial Officer, effective September 21, 2026, according to a company statement. Garner will oversee global finance functions including financial planning and analysis, accounting, treasury, tax, investor relations, and internal audit.</p> <p>Garner joins Avantor from CONMED Corporation, where he served as Executive Vice President and CFO from 2018 to 2026. He brings more than 30 years of finance, operational, and public company leadership experience. Prior to CONMED, he held several roles at C. R. Bard, Inc., including Vice President of Investor Relations and Division CFO.</p> <p>Garner holds a bachelor http://www.streetinsider.com/Management+Changes/Avantor+names+Todd+Garner+as+CFO+effective+Sept.+21/27082503.html Mon, 21 Sep 2026 06:05:14 -0400 AVTR